Copyright
©The Author(s) 2022.
World J Clin Cases. Oct 6, 2022; 10(28): 10085-10096
Published online Oct 6, 2022. doi: 10.12998/wjcc.v10.i28.10085
Published online Oct 6, 2022. doi: 10.12998/wjcc.v10.i28.10085
Figure 1 Rates of patients with undetectable hepatitis B virus DNA through week 192.
A: Proportion of patients with HBV DNA < 20 IU/mL in Group A and B in HBeAg positive (+) patients; B: Proportion of patients with HBV DNA < 20 IU/mL in Groups A and B in HBeAg negative (-) patients. HBeAg: Hepatitis B e antigen.
- Citation: Xu JH, Wang S, Zhang DZ, Yu YY, Si CW, Zeng Z, Xu ZN, Li J, Mao Q, Tang H, Sheng JF, Chen XY, Ning Q, Shi GF, Xie Q, Zhang XQ, Dai J. One hundred and ninety-two weeks treatment of entecavir maleate for Chinese chronic hepatitis B predominantly genotyped B or C. World J Clin Cases 2022; 10(28): 10085-10096
- URL: https://www.wjgnet.com/2307-8960/full/v10/i28/10085.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v10.i28.10085